⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885178 | 0.86 | — | — | |
| SCHEMBL31180268 | 0.86 | — | — | |
| SCHEMBL31337163 | 0.86 | — | — | |
| SCHEMBL30179223 | 0.86 | CHRNA7 (0.33) | — | |
| Ammonia Solution, Strong SCHEMBL31381430 | 0.80 | — | — | |
| Ammonia Solution, Strong SCHEMBL673260 | 0.76 | — | — | |
| SCHEMBL360431 | 0.76 | ALDH1A1 (0.42) | — | |
| SCHEMBL27512 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL22129587 | 0.76 | ALDH1A1 (0.42) | — | |
| Sodium Chloride SCHEMBL10420778 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521708-B2 | Doped anion exchange membranes (AEMs) for highly selective separators in electrochemical devices | WASHINGTON UNIVERSITY (US) | 2026-01-13 | — | — | US | disclosed |
| US-6706747-B2 | TREATING ELEVATED INTRAOCULAR PRESSURE, DEPRESSION, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY WHICH IS ALLEVIATED BY TREATMENT WITH AN ALPHA 2 BLOCKING AGENT | ALLERGAN, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030187047-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6569884-B2 | Trans-2-(3-phenyl-bicyclo(2.2.1)heptyl)-2-aminooxazoline, for example; treating intraocular pressure, noninsulin-dependent diabetes, male impotence and obesity | ALLERGAN | 2003-05-27 | — | — | US | disclosed |
| US-20020049241-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2002-04-25 | — | — | US | disclosed |
| EP-0770068-B1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS ALPHA 2-ADRENERGIC BLOCKING AGENTS | ALLERGAN SALES INC (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6319935-B1 | USED IN TREATMENT OF ELEVATED INTRAOCULAR PRESSURE, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY | ALLERGAN SALES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6150389-A | ANTIDEPRESSANTS; TREATING ELEVATED INTRAOCULAR PRESSURE, E.G., GLAUCOMA; ANTIDIABETIC AGENTS FOR NON-INSULIN DEPENDENT DIABETES, SEXUAL DISORDERS, E.G., MALE IMPOTENCE AND OBESITY; E.G. TRANS-2-(3-PHENYL-BICYCLO(2.2.1)HEPTYL)-2-AMINOOXAZOLINE | ALLERGAN SALES, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0770068-A1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS ALPHA 2-ADRENERGIC BLOCKING AGENTS | Allergan (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001813-A1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS α2-ADRENERGIC BLOCKING AGENTS | ALLERGAN (US) | 1996-01-25 | — | — | WO | disclosed |